MedTrace Logo

Oophorectomy, Estrogen Therapy and Cardiovascular Disease Risk in Young Women

NCT03815929 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2024-10-23

Study results available
· View outcomes & findings →

Summary

Researchers are trying to assess the appropriate dose of estrogen for decreasing the risk of cardiovascular disease in women who have removal of their ovaries at a young age, before the age of 46 years.

Conditions

  • Cardiovascular Risk Reduction

Interventions

DRUG

Estradiol 100 Micrograms Patch

Standard

DRUG

Estradiol Patch

Individualized

Sponsors & Collaborators

Principal Investigators

  • Ekta Kapoor, MBBS · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-03-15
Primary Completion
2023-08-28
Completion
2023-08-28
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03815929 on ClinicalTrials.gov